好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2017 Annual Meeting | C224 - Controversies in Multiple Sclerosis Therapy

Friday 04/28/17
07:00 AM - 09:00 AM Add To Calendar
This program will be presented both in-person and online
This program is not expected to be available in the meeting's On Demand product.
Seminar
Riley Bove, MD, FAAN
Participants should be able to describe and discuss the relative pros and cons of a number of controversies in MS evaluation and therapy.
2.00 CME credits
Patient Care & Procedural Skills, Interpersonal and Communication Skills, Medical Knowledge, Practice-based Learning and Improvement
Trainee, General Neurologist, Specialist Neurologist
Case-based, Didactic, Audience Participation
Event Timeline
07:00 AM - 07:20 AM Speaker All Patients with CIS and RIS Should Start MS Therapy
Riley Bove, MD, FAAN
07:20 AM - 07:30 AM Q&A Questions and Answers
07:30 AM - 07:50 AM Speaker All JCV Positive MS Patients Should Discontinue Natalizumab Therapy
Bruce A. Cree, MD, PhD, MAS, FAAN
07:50 AM - 08:00 AM Q&A Questions and Answers
08:00 AM - 08:20 AM Speaker All Patients with MS Should Be Treated with Vitamin D Supplementation
Ellen M. Mowry, MD, FAAN
08:20 AM - 08:30 AM Q&A Questions and Answers
08:30 AM - 08:50 AM Speaker Once Started, MS Therapies Should Be Continued for Life
Ellen M. Mowry, MD, FAAN
08:50 AM - 09:00 AM Q&A Questions and Answers
Faculty Disclosures
Riley Bove, MD, FAAN Dr. Bove has nothing to disclose.
Bruce A. Cree, MD, PhD, MAS, FAAN The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for EMD Serono. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Autobahn. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avotres. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyverna. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. The institution of Dr. Cree has received research support from Kyverna. Dr. Cree has received publishing royalties from a publication relating to health care.
Ellen M. Mowry, MD, FAAN Dr. Mowry has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Octave. Dr. Mowry has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SetPoint. The institution of Dr. Mowry has received research support from Genentech/Roche. The institution of Dr. Mowry has received research support from Biogen. Dr. Mowry has received publishing royalties from a publication relating to health care.